麻豆女优

Skip to main content

The independent source for health policy research, polling, and news.

Subscribe Follow Us
  • Trump 2.0

    Trump 2.0

    • Agency Watch
    • State Watch
    • Rural Health Payout
  • Public Health

    Public Health

    • Vaccines
    • CDC & Disease
    • Environmental Health
  • Audio Reports

    Audio Reports

    • What the Health?
    • Health Care Helpline
    • 麻豆女优 Health News Minute
    • An Arm and a Leg
    • Health Hub
    • HealthQ
    • Silence in Sikeston
    • Epidemic
    • See All Audio
  • Special Reports

    Special Reports

    • Bill Of The Month
    • The Body Shops
    • Broken Rehab
    • Deadly Denials
    • Priced Out
    • Dead Zone
    • Diagnosis: Debt
    • Overpayment Outrage
    • Opioid Settlement Tracking
    • See All Special Reports
  • More Topics

    More Topics

    • Elections
    • Health Care Costs
    • Insurance
    • Prescription Drugs
    • Health Industry
    • Immigration
    • Reproductive Health
    • Technology
    • Rural Health
    • Race and Health
    • Aging
    • Mental Health
    • Affordable Care Act
    • Medicare
    • Medicaid
    • Children’s Health

  • Medicaid Work Mandate
  • Suicide Prevention
  • Community Health Workers
  • Rural Health Payout
  • Opioid Crisis

TRENDING TOPICS:

  • Medicaid Work Mandate
  • Suicide Prevention
  • Community Health Workers
  • Rural Health Payout
  • Opioid Crisis

Morning Briefing

Summaries of health policy coverage from major news organizations

  • Email

Tuesday, Aug 29 2023

Full Issue

Diabetes Drugs, Blood Thinner On Medicare's List Of 10 Meds To Negotiate Prices

HHS released its list of 10 drugs that will be on the table for the first-ever price negotiations between Medicare and drugmakers. Included in the mix are medications that treat diabetes, autoimmune disease, rheumatoid arthritis, and heart failure. The process is facing multiple court challenges.

The blood thinner Eliquis and popular diabetes treatments including Jardiance are among the first drugs that will be targeted for price negotiations in an effort to cut Medicare costs. President Joe Biden鈥檚 administration on Tuesday released a list of 10 drugs for which the federal government will take a first-ever step: negotiating drug prices directly with the manufacturer. (Murphy, Seitz and Megerian, 8/29)

The drugs include Eliquis, Jardiance, Xarelto, Januvia, Farxiga, Entresto, Enbrel, Imbruvica, Stelara, and insulins that go by names including Fiasp and NovoLog. The new prices will be announced on Sept. 1, 2024 and will go into effect on Jan. 1, 2026. The drugs were chosen from a list of 50 drugs that cost Medicare鈥檚 pharmacy drug benefit the most money. (Cohrs, 8/29)

The drugs listed Tuesday are among the top 50 with the highest spending for Medicare Part D, which covers prescription medications that seniors fill at retail pharmacies. The 10 medicines accounted for $50.5 billion, or about 20%, of total Part D prescription drug costs from June 1, 2022, to May 31, 2023, according to the Centers for Medicare and Medicaid Services, or CMS.聽 (Constantino, 8/29)

When could Medicare patients who take one of the 10 drugs pay less? Jan. 1, 2026. However, several factors could complicate that timeline. This includes the outcomes of several lawsuits challenging the constitutionality of the law and the outcomes of the 2024 presidential elections. If the law goes forward as prescribed, then the final negotiated price for the products won鈥檛 be reached until Sept. 1, 2024. (King and Lim, 8/28)

In the year since the passage of Democrats' drug pricing law, pharmaceutical companies and venture capitalists have shifted their priorities and placed less emphasis on developing synthetic drugs that will be subject to price negotiations faster than biologics. Pharmaceutical interests say it's proof that Democrats' signature health policy achievement is driving investment away from some mainstays of modern medicine. (Reed, 8/29)

In related news about drug prices 鈥

Texans struggling with skyrocketing medication costs could see relief under a new program that allows distributors to import cheaper drugs from Canada. House Bill 25 creates the 鈥淲holesale Prescription Drug Importation Program.鈥 The state鈥檚 Health and Human Services Commission would contract with Canadian drug wholesalers and suppliers to bring safe, eligible prescription drugs to Texas consumers at prices far cheaper than U.S. wholesalers. (Harper, 8/29)

This is part of the Morning Briefing, a summary of health policy coverage from major news organizations. Sign up for an email subscription.
Newsletter icon

Sign Up For Our Newsletter

Stay informed by signing up for the Morning Briefing and other emails:

Recent Morning Briefings

  • Today, April 29
  • Tuesday, April 28
  • Monday, April 27
  • Friday, April 24
  • Thursday, April 23
  • Wednesday, April 22
More Morning Briefings
RSS Feeds
  • Podcasts
  • Special Reports
  • Morning Briefing
  • About Us
  • Republish Our Content
  • Contact Us

Follow Us

  • RSS

Sign up for emails

Join our email list for regular updates based on your personal preferences.

Sign up
  • Editorial Policy
  • Privacy Policy

漏 2026 麻豆女优